ME02102B - Novi polimorf - Google Patents

Novi polimorf

Info

Publication number
ME02102B
ME02102B MEP-2015-56A MEP5615A ME02102B ME 02102 B ME02102 B ME 02102B ME P5615 A MEP5615 A ME P5615A ME 02102 B ME02102 B ME 02102B
Authority
ME
Montenegro
Prior art keywords
solid form
form according
nocturia
vasopressin
solvate
Prior art date
Application number
MEP-2015-56A
Other languages
English (en)
Unknown language (me)
Inventor
Björn Erik Johanson
Johan Henrik Kjellström
Thomas Vilhelmsen
Original Assignee
Vantia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia Ltd filed Critical Vantia Ltd
Publication of ME02102B publication Critical patent/ME02102B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
MEP-2015-56A 2010-04-01 2011-03-31 Novi polimorf ME02102B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1005623.2A GB201005623D0 (en) 2010-04-01 2010-04-01 New polymorph
US34704810P 2010-05-21 2010-05-21
EP11714079.8A EP2552910B1 (en) 2010-04-01 2011-03-31 New polymorph
PCT/GB2011/000500 WO2011121308A1 (en) 2010-04-01 2011-03-31 New polymorph

Publications (1)

Publication Number Publication Date
ME02102B true ME02102B (me) 2015-10-20

Family

ID=42228830

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-56A ME02102B (me) 2010-04-01 2011-03-31 Novi polimorf

Country Status (20)

Country Link
US (1) US9079881B2 (enExample)
EP (1) EP2552910B1 (enExample)
JP (1) JP5802737B2 (enExample)
KR (1) KR101792621B1 (enExample)
CN (1) CN102918038B (enExample)
CA (1) CA2795109C (enExample)
DK (1) DK2552910T3 (enExample)
ES (1) ES2538085T3 (enExample)
GB (1) GB201005623D0 (enExample)
HR (1) HRP20150513T1 (enExample)
HU (1) HUE026442T2 (enExample)
ME (1) ME02102B (enExample)
MX (1) MX2012011382A (enExample)
PL (1) PL2552910T3 (enExample)
PT (1) PT2552910E (enExample)
RS (1) RS53956B1 (enExample)
RU (1) RU2559633C2 (enExample)
SI (1) SI2552910T1 (enExample)
SM (1) SMT201500107B (enExample)
WO (1) WO2011121308A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
JP7304043B2 (ja) * 2015-07-22 2023-07-06 アナベックス ライフ サイエンシズ コーポレイション テトラヒドロ-n,n-ジメチル-2,2-ジフェニル-3-フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
CN1183134C (zh) 1997-07-30 2005-01-05 惠氏公司 三环后叶加压素激动剂
JP2001512120A (ja) 1997-07-30 2001-08-21 アメリカン・ホーム・プロダクツ・コーポレイション 三環系バソプレシンアゴニスト
CA2358894A1 (en) 1999-02-04 2000-08-10 American Home Products Corporation Tricyclic pyridine n-oxides vasopressin agonists
AU2603000A (en) 1999-02-04 2000-08-25 American Home Products Corporation Thienylbenzoylbenzazepines as vasopressin agonists
CN1339035A (zh) 1999-02-04 2002-03-06 美国家用产品公司 吡啶并苯并二吖庚因和吡啶并苯并氧杂吖庚因酰胺血管加压素激动剂
DE60000969D1 (de) 1999-02-04 2003-01-23 Wyeth Corp Pyrrolobenzodiazepine carboxamide vasopressin agonisten
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0015601D0 (en) * 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents

Also Published As

Publication number Publication date
JP2013523706A (ja) 2013-06-17
US9079881B2 (en) 2015-07-14
WO2011121308A1 (en) 2011-10-06
GB201005623D0 (en) 2010-05-19
KR101792621B1 (ko) 2017-11-02
HUE026442T2 (en) 2016-06-28
ES2538085T3 (es) 2015-06-17
CA2795109C (en) 2018-04-17
SI2552910T1 (sl) 2015-06-30
SMT201500107B (it) 2015-07-09
RU2012146544A (ru) 2014-05-10
RU2559633C2 (ru) 2015-08-10
RS53956B1 (sr) 2015-08-31
PT2552910E (pt) 2015-05-13
MX2012011382A (es) 2013-01-29
KR20130023218A (ko) 2013-03-07
HRP20150513T1 (hr) 2015-06-05
EP2552910B1 (en) 2015-03-11
EP2552910A1 (en) 2013-02-06
CN102918038A (zh) 2013-02-06
DK2552910T3 (en) 2015-04-07
US20140296213A1 (en) 2014-10-02
CA2795109A1 (en) 2011-10-06
JP5802737B2 (ja) 2015-11-04
CN102918038B (zh) 2015-09-09
PL2552910T3 (pl) 2015-07-31

Similar Documents

Publication Publication Date Title
HRP20150513T1 (hr) Novi polimorf
GB202106881D0 (en) Therapeutic solid dosage forms
ES2659758T3 (es) Antagonistas de receptores de 5-HT3
IL260297A (en) Process for preparing n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino )–benzamide
NZ603043A (en) Pharmaceutical compositions comprising cftr modulators and administrations thereof
EP4574210A3 (en) Kappa opioid receptor antagonists and products and methods related thereto
HRP20192132T1 (hr) Antagonist nk-1/nk-3 receptora za liječenje valunga
JP2012036197A5 (enExample)
HRP20171151T1 (hr) Inhibitori cdc7
HRP20151299T1 (hr) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
JP2017514910A5 (enExample)
JP2014162794A5 (enExample)
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
IL214036A (en) Methods for determining the exact amount of particles in the inhaled preparation
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
NZ628993A (en) Pharmaceutical formulations comprising ccr3 antagonists
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
MX350903B (es) Anticuerpos anti-cd38.
GEAP201914563A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX356105B (es) Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida.
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MX2015011536A (es) Nuevos antagonistas de receptores trpa1 de sulfamidas.
PH12013502691A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
EA201101207A1 (ru) Применение антагонистов рецептора nk
WO2014014794A3 (en) Mineralocorticoid receptor antagonists